Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival benefit for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
Final results from the CheckMate 204 study confirm durable responses from the combination therapy — which...
